secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001104659-25-122786
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe
--------------------------------------------------------------------------------

- Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.
- Cash $8.1M at Sept 30, 2025; $14.9M net from ATM after quarter-end; no debt mentioned.
- Expenses fell $4.6M YoY due to lower R&D, partly offset by higher SG&A for European launch.
- FDA PDUFA goal date for ONS-5010 is Dec 31, 2025; awaiting U.S. approval decision.
- LYTENAVA accepted into UK tender framework in Dec 2025; launch expanding to Austria and Netherlands.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/0001104659-25-122786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer